Literature DB >> 2521831

Differential binding of IL-1 alpha and IL-1 beta to receptors on B and T cells.

G Scapigliati1, P Ghiara, M Bartalini, A Tagliabue, D Boraschi.   

Abstract

The interleukin 1 receptors (IL-1R) on the human B lymphoma RAJI and on the murine thymoma EL4-6.1 have been characterized. Equilibrium binding analysis using both 125I-labeled IL-1 alpha and IL-1 beta showed that RAJI cells have a higher number of binding sites/cell for IL-1 beta (2400, Kd 2.2 nM) than for IL-1 alpha (316, Kd 0.13 nM). On the other hand, EL4-6.1 cells have more receptors/cell for IL-1 alpha (22 656, Kd 1 nM) than for IL-1 beta (2988, Kd 0.36 nM). Dexamethasone (DXM) induced on RAJI cells a time-dependent increase in binding sites for both IL-1 beta and IL-1 alpha without affecting their binding affinities. However, while receptor-bound 125I-IL-1 alpha was displaced with equal efficiency by both IL-1 forms, only unlabeled IL-1 beta could effectively displace 125I-IL-1 beta. Cross-linking experiments indicated that RAJI cells have a predominant IL-1R of about 68 kDa, while EL4-6.1 cells have an IL-1-binding polypeptide of 80 kDa. These results suggest that B and T cells possess structurally different IL-1R with distinct binding properties for IL-1 alpha and IL-1 beta.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521831     DOI: 10.1016/0014-5793(89)80169-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Superoxide generation by EBV-transformed B lymphocytes. Activation by IL-1 beta, TNF-alpha and receptor independent stimuli.

Authors:  J T Hancock; L M Henderson; O T Jones
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

2.  Preferential localization of systemically administered radiolabeled interleukin 1alpha in experimental inflammation in mice by binding to the type II receptor.

Authors:  C J van der Laken; O C Boerman; W J Oyen; M T van de Ven; R Chizzonite; F H Corstens; J W van der Meer
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

3.  Cytokine modulation of liver annexin 1 expression during experimental endotoxemia.

Authors:  C de Coupade; M N Ajuebor; F Russo-Marie; M Perretti; E Solito
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 4.  Interleukin 1 receptors and biological responses.

Authors:  C A Dinarello; B D Clark; T Ikejima; A J Puren; N Savage; P M Rosoff
Journal:  Yale J Biol Med       Date:  1990 Mar-Apr

5.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone.

Authors:  J W Smith; T L McDonald
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

7.  The zinc finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest.

Authors:  S F Sells; S Muthukumar; V P Sukhatme; S A Crist; V M Rangnekar
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

8.  Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1.

Authors:  P Bossù; U Visconti; P Ruggiero; G Macchia; M Muda; R Bertini; C Bizzarri; A Colagrande; V Sabbatini; G Maurizi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

9.  Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.

Authors:  R M Burch; L C Mahan
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

10.  A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types.

Authors:  C J McMahan; J L Slack; B Mosley; D Cosman; S D Lupton; L L Brunton; C E Grubin; J M Wignall; N A Jenkins; C I Brannan
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.